The current risk assessment paradigm in relation to the regulation of nanotechnologies

International Handbook on Regulating Nanotechnologies

Volumn , Issue , 2010, Pages 124-143

  Chaudhry, Qasim ^a   Bouwmeester, Hans ^b   Hertel, Rolf F ^c  

^a UNIVERSITY OF CHESTER   (United Kingdom)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881949121     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (66)

1. American Heritage Dictionary (ed.) (2007), American Heritage Medical Dictionary, New York: Houghton Mifflin.
2. Aprahamian, M., C. Michel, W. Humbert, J.P. Devissaguet and C. Damge (1987), 'Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small-intestine', Biology of the Cell, 61, 69-76.
3. Balbus, J.M., A.D. Maynard, V.L. Colvin et al. (2007), 'Hazard assessment for nanoparticles - report from an interdisciplinary workshop', Environmental Health Perspective, 115, 1654-9.
4. Ballou, B., B.C. Lagerholm, L.A. Ernst, M.P Bruchez and A.S. Waggoner (2004), 'Noninvasive imaging of quantum dots in mice', Bioconjugate Chemistry, 15, 79-86.
5. BAuA, BfR and UBA (2007), Nanotechnology: Health and Environmental Risks of Nanomaterials - Research Strategy, accessed 29 April 2009 at www.bfr.bund.de.
6. Blood, D.C., V.P. Studdert and C.C. Gay (2006), Saunders Comprehensive Veterinary Dictionary, 3rd edn, New York: Elsevier.
7. Borm, P., F.C. Klaessig, T.D. Landry, et al. (2006), 'Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles', Toxicological Sciences, 90, 23-32.
8. Boxall, A.B.A., Q. Chaudhry, C. Sinclair, et al. (2007), Current and Predicted Environmental Exposure to Engineered Nanoparticles, York: Central Science Laboratory.
9. Carr, K.E., R.A. Hazzard, S. Reid and G.M. Hodges (1996), 'The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes', Pharmaceutical Research, 13, 1205-9.
10. Cedervall, T., I. Lynch, M. Foy, et al. (2007), 'Detailed identification of plasma proteins adsorbed on copolymer nanoparticles', Angewandte Chemie International Edition, 46, 5754-6.
11. Chaudhry, Q., J. Blackburn, P. Floyd, et al. (2006), A Scoping Study to Identify Regulatory Gaps for the Products and Applications of Nanotechnologies, York: Central Science Laboratory.
12. Chaudhry, Q., C. George and R. Watkins (2007), 'Nanotechnology regulation - developments in the United Kingdom', in Graeme A. Hodge, Diana M. Bowman and Karinne Ludlow (eds) (2007), New Global Frontiers in Regulation: The Age of Nanotechnology, Cheltenham, UK and Northampton, MA, USA: Edward Elgar, pp. 212-38.
13. Chen, Z., H. Meng, G. Xing, et al. (2006), 'Acute toxicological effects of copper nanoparticles in vivo', Toxicology Letters, 163, 109-20.
14. Crane, M. and R.D. Handy (2006), An Assessment of Regulatory Testing Strategies and Methods for Characterizing the Ecotoxicological Hazards of Nanomaterials, London: Defra.
15. De Jong, W.H., W.I. Hagens, P. Krystek, M.C. Burger, A.J. Sips and R.E. Geertsma (2008), 'Particle size-dependent organ distribution of gold nanoparticles after intravenous administration', Biomaterials, 29, 1912-19.
16. des Rieux, A., V. Fievez, M. Garinot, Y.J. Schneider and V. Preat (2006), 'Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach', Journal of Control Release, 116, 1-27.
17. Dobrovolskaia, M. (2007), 'Immunological properties of engineered nanomaterials', Nature Nanotechnology, 2, 469-78.
18. Donaldson, K., V. Stone, A. Clouter, L. Renwick and W. MacNee (2001), 'Ultrafine particles', Journal of Occupational Environmental Medicine, 58, 211-16.
19. ETC Group (2004), Down on the Farm: The Impact of Nano-scale Technologies on Food Agriculture, Ottawa: ETC Group.
20. European Chemicals Agency (2009) Guidance on Information Requirements and Chemical Safety Assessment, accessed 5 June 2009 at guidance.echa.europa.eu/docs/guidance_document/information_requirements_en.htm?time=1251199014.
21. European Commission (2004), Towards a European Strategy for Nanotechnology - Communication from the Commission, Brussels: EC.
22. Feynman, R. (1959), There's Plenty of Room at the Bottom, accessed 29 April 2009 at www.its.caltech.edu/~feynman/plenty.html.
23. Florence, A.T. (2005), 'Nanoparticle uptake by the oral route: fulfilling its potential?', Drug Discovery Today: Technologies, 2, 75-81.
24. Franco, A., S.F. Hansen, S.I. Olsen and L. Butti (2007), 'Limits and prospects of the ''incremental approach'' and the European legislation on the management of risks related to nanomaterials', Regulatory Toxicology and Pharmacology, 48, 171-83.
25. Friends of the Earth Australia (2008), Out of the Laboratory and on to Our Plates - Nanotechnology in Food & Agriculture, Melbourne, VIC: FoE Australia, Europe and the US.
26. Gergely, A. (2007), 'Regulation of nanotechnology - within REACH?', Nano Now, February, 44-6.
27. Hagens, W.I., A.G. Oomen, W.H. de Jong, F.R. Cassee and A.J. Sips (2007), 'What do we (need to) know about the kinetic properties of nanoparticles in the body?', Regulatory Toxicology and Pharmacology, 49, 217-29.
28. Health Council Netherlands (2006), Health Significance of Nanotechnologies, The Hague, The Health Council of the Netherlands.
29. Hillery, A.M., P.U. Jani and A.T. Florence (1994), 'Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles', Journal of Drug Targeting, 2, 151-6.
30. Hillyer, J.F. and R.M. Albrecht (2001), 'Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles', Journal of Pharmaceutical Sciences, 90, 1927-36.
31. Hoet, P., I. Bruske-Hohlfeld and O. Salata (2004), 'Nanoparticles - known and unknown health risks', Journal of Nanobiotechnology, 2, 1-15.
32. Jani, P., G.W. Halbert, J. Langridge and A.T. Florence (1990), 'Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency', Journal of Pharmacy and Pharmacology, 42(12), 821-6.
33. Jia, X., N. Li and J. Chen (2005), 'A subchronic toxicity study of elemental nano-Se in Sprague-Dawley rats', Life Sciences, 76, 1989-2003.
34. Lewinski, N., V. Colvin and R. Drezek (2008), 'Cytotoxicity of nanoparticles', Small, 4, 26-49.
35. Lynch, I. and K.A. Dawson (2008), 'Protein-nanoparticle interactions', Nano Today, 3, 40-47.
36. Maynard, A.D., R.J. Aitken, T. Butz, et al. (2006), 'Safe handling of nanotechnology', Nature, 444, 267-9.
37. Maynard A.D. and R.J. Aitken (2007), 'Assessing exposure to airborne nanomaterials: current abilities and future requirements', Nanotoxicology, 1, 26-41.
38. Michaelis, K., M.M. Hoffmann, S. Dreis, et al. (2006), 'Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain', Journal of Pharmacology and Experimental Therapeutics, 317, 1246-53.
39. Morgan, K. (2005), 'Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles', Risk Analysis, 25, 1621-35.
40. National Academy of Science (1983), Risk Assessment in Federal Government: Managing the Process, Washington, DC: National Academy Press.
41. National Nanotechnology Initiative (2001), Leading to the Next Industrial Revolution, accessed 29 April 2009 at http://clinton4.nara.gov/WH/New/html/20000121_4.html.
42. Nel, A., T. Xia, L. Madler and N. Li (2006), 'Toxic potential of materials at the nanolevel', Science, 311, 622-7.
43. Nemmar, A., P.H.M. Hoet, B. Vanquickenborne, et al. (2002), 'Passage of inhaled particles into the blood circulation in humans', Circulation, 105, 411-14.
44. Oberdörster, G., A.D. Maynard, K. Donaldson, et al. (2005), 'Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy', Particle Fibre Toxicology, 2, 8.
45. Oberdörster, G., E. Oberdörster and J. Oberdörster (2007), 'Concepts of nanoparticle dose metric and response metric', Environmental Health Perspective, 115, A290.
46. OECD Working Party on Manufactured Nanomaterials Preliminary (2009), Review of OECD Test Guidelines for their Applicability to Manufactured Nanomaterials, ENV/CHEM/NANO(2009)6/REV1, Paris: Environment Directorate, OECD.
47. Poland, C.A., R. Duffin, I. Kinloch, et al. (2008), 'Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study', Nature Nanotechnology, 3, 423-8.
48. Rocks, S., S. Pollard, R. Dorey, L. Levy, P. Harrison and R. Handy (2008), Comparison of RA Approaches for Manufactured Nanomaterials, London: Defra.
49. Roszek, B., W. de Jong and R. Geertsma (2005), Nanotechnology in Medical Applications: State-of-the-art in Materials and Devices, Bilthoven, Netherlands: Department of Pharmaceutical Affairs and Medical Technology of the Dutch Ministry of Health, Welfare and Sport.
50. Rothen-Rutishauser, B.M., S. Schurch, B. Haenni, N. Kapp and P. Gehr (2006), 'Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques', Environmental Science and Technology, 40, 4353-9.
51. Royal Society and Royal Academy of Engineering (2004), Nanoscience Nanotechnologies: Opportunities Uncertainties, London: RS-RAE.
52. Sadauskas, E., H. Wallin, M. Stoltenberg, et al. (2007), 'Kupffer cells are central in the removal of nanoparticles from the organism', Particle and Fibre Toxicology, 4, 10.
53. Scientific Committee on Emerging and Newly Identified Health Risk (2007a), Scientific Committee on Emerging and Newly Identified Health Risk - SCENIHR. Opinion on the Scientific Aspects of the Existing and Proposed Definitions Relating to Products of Nanoscience and Nanotechnologies, Brussels: European Commission Health & Consumer Protection Directorate-General.
54. Scientific Committee on Emerging and Newly Identified Health Risk (2007b), Scientific Committee on Emerging and Newly Identified Health Risk - SCENIHR. Opinion on the Appropriateness of the RA Methodology in Accordance with the Technical Guidance Documents for New and Existing Substances for Assessing the Risks of Nanomaterials, Brussels: European Commission Health & Consumer Protection Directorate-General.
55. Scientific Committee on Emerging and Newly Identified Health Risk (2009), Scientific Committee on Emerging and Newly Identified Health Risks, Risk Assessment of Products of Nanotechnologies, Brussels: European Commission Health & Consumer Protection Directorate-General.
56. Silva, G.A. (2007), 'Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier', Surgical Neurology, 67, 113-6.
57. Šimon, P. and E. Joner (2008), 'Conceivable interactions of biopersistent nanoparticles with food matrix and living systems following from their physicochemical properties', Journal of Food and Nutrition Research, 47, 51-9.
58. Singh, R., D. Pantarotto, L. Lacerda, et al. (2006), 'Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers', Proceedings of the National Academy of Sciences, 103, 3357-62.
59. Soil Association (2008), 'Soil Association first organisation in the world to ban nanoparticles - potentially toxic beauty products that get right under your skin', press release, Bristol: SA.
60. Tiede, K., A.B.A. Boxall, S.P. Tear, J. Lewis, H. David and M. Hassellov (2008), 'Detection and characterization of engineered nanoparticles in food and the environment', Food Additives & Contaminants, 25, 795-821.
61. Tran, C.L., K. Donaldson, V. Stones, et al. (2005), A Scoping Study to Identify Hazard Data Needs for Addressing Risks Presented by Nanoparticles and Nanotubes, Edinburgh: Institute of Occupational Medicine.
62. Tsuchiya, T., I. Oguri, Y. Nakajima and N. Miyata (1996), 'Novel harmful effects of [C60] fullerene on mouse embryos in vitro and in vivo', FEBS Letters, 393, 139-45.
63. Wang, B., W.Y. Feng, M. Wang, et al. (2008), 'Acute toxicological impact of nano-and submicro-scaled zinc oxide powder on healthy adult mice', Journal of Nanoparticle Research, 10, 263-76.
64. Wang, B., W.Y. Feng, T.C. Wang, et al. (2006), 'Acute toxicity of nano-and micro-scale zinc powder in healthy adult mice', Toxicology Letters, 161, 115-23.
65. Wang, J., G. Zhou, C. Chen, et al. (2007), 'Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration', Toxicology Letters, 168, 176-85.
66. Zhang, J., H. Wang, X. Yan and L. Zhang (2005), 'Comparison of short-term toxicity between nano-Se and selenite in mice', Life Sciences, 76, 1099-109.